Vol 7 (January 31, 2026): Translational Breast Cancer Research

Editorial Commentary 
CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL
Eriko Tokunaga
Translational Breast Cancer Research  
2026;
7:
10
.
 (31 January 2026) 
PDF Full Text (326) Peer Review File COI Form Open Access Get Permission
Expert Consensus 
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)
Yang Yuan, Yongmei Yin, Shu Wang, Yueping Liu, Jin Yang, Min Yan, Xueli Mo, Yueyin Pan, Xiaojia Wang, Haibo Wang, Jianbin Li, Shusen Wang, Jiong Wu, Erwei Song, Zefei Jiang; Chinese Consensus Group on Breast Cancer Endocrine Therapy
Translational Breast Cancer Research  
2026;
7:
9
.
 (31 January 2026) 
PDF Full Text (1665) Peer Review File COI Form Open Access Get Permission
Review Article 
Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review
Athina Stravodimou, Ioannis A. Voutsadakis
Translational Breast Cancer Research  
2026;
7:
8
.
 (31 January 2026) 
PDF Full Text (353) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Review Article 
BRCA and CDK4/6: allies or antagonists?—efficacy of CDK4/6 inhibitors in HR+/HER2− breast cancer with germline BRCA1/2 mutations: a narrative review
Maria Florencia Illia, Giuliana Colucci, Andres Rodriguez Mignola, Mariana Eiben, Angeles María Ballester, Natalia Zeff, Fernando Paesani, Gabriel Crimi, Francisco Von Stecher, Maximo de la Vega, Florencia Perazzo, Pablo Mandó
Translational Breast Cancer Research  
2026;
7:
7
.
 (31 January 2026) 
PDF Full Text (1004) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Original Article 
The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells
Miao Yang, Jia-Qun Zou, Wei Yang
Translational Breast Cancer Research  
2026;
7:
6
.
 (31 January 2026) 
PDF Full Text (142) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Original Article 
Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a comprehensive clinicopathologic and molecular analysis in Chinese patients
Shuo Zhang, Tianli Hui, Wei Gao, Jiajie Shi, Meng Cheng, Mengxiao Wang, Dongsheng Chen, Xing Zhang, Yuan Tan, Cuizhi Geng
Translational Breast Cancer Research  
2026;
7:
5
.
 (31 January 2026) 
PDF Full Text (183) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Original Article 
Social inequalities in survival among women with breast cancer in southeastern Brazil: a retrospective cohort study
Raphael Manhães Pessanha, Wesley Rocha Grippa, Luiz Cláudio Barreto Silva Neto, Larissa Soares Dell’Antonio, Cristiano Soares da Silva Dell’Antonio, Luís Carlos Lopes-Júnior
Translational Breast Cancer Research  
2026;
7:
4
.
 (31 January 2026) 
PDF Full Text (243) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Original Article 
Comparison of male breast cancer in China and the US: a real-world cohort study
Yuxuan Gao, Mengmeng Zhang, Jianyun Nie, Guolin Ye, Gang Sun, Li Ma, Hebing Wang, Zefei Jiang, Ying Lin
Translational Breast Cancer Research  
2026;
7:
3
.
 (31 January 2026) 
PDF Full Text (350) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Original Article 
Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China
Binliang Liu, Tao Wu, Kaili Lu, Jun Chen, Qiang Zhou, Liping Liu, Can Tian, Zhe-Yu Hu, Yu Tang, Quchang Ouyang, Ning Xie
Translational Breast Cancer Research  
2026;
7:
2
.
 (31 January 2026) 
PDF Full Text (646) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Original Article 
Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: insights from a large cohort in central south China
Jianmin Wu, Ziru Zhao, Mengxi Li, Jing Cao, Kejing Zhang
Translational Breast Cancer Research  
2026;
7:
1
.
 (31 January 2026) 
PDF Full Text (403) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission